Table 1.

Demographic and baseline data for patients who completed the trial by December 2011

Demographic
Completed trial N (% of those contacted)	112 (31.7 %)
Nationality N (%)
German	84 (75 %)
Turkish	14 (13 %)
Russian	9 (8 %)
Other	5 (4 %)
Gender – male N (%)	59 (53 %)
Age mean (median; min, max) years	18 (15.7; 4, 45)
Baseline Phe levels mean (median; min, max) μmol/L	795.3 (754.5; 340.8, 1884)
Baseline Phe tolerance mean (median; min, max) mg/kg	14.88 (12.4; 2.84, 51.19)
Sapropterin responsive patients N (%)	46 (41.1 %)
Responsive at 10 mg/kg/day	22 (19.6 %)
Responsive only at 20 mg/kg/day	24 (21.4 %)